Full Name: CureYLD - Curing Youth Leukodystrophies
Headquarters: Boston, Massachusetts, USA
Founded: 2019
Focus: Rare neurological diseases, leukodystrophies, gene therapy
Status: 501(c)(3) nonprofit organization
Website: [cureyld.org](https://www.cureyld.org)
Overview
flowchart TD
companies_cureyld["CureYLD"]
style companies_cureyld fill:#4fc3f7,stroke:#333,color:#000
companies_cureyld_0["Mission and Vision"]
companies_cureyld -->|"includes"| companies_cureyld_0
style companies_cureyld_0 fill:#81c784,stroke:#333,color:#000
companies_cureyld_1["Science of Leukodystrophies"]
companies_cureyld -->|"includes"| companies_cureyld_1
style companies_cureyld_1 fill:#ef5350,stroke:#333,color:#000
companies_cureyld_2["Disease Mechanism"]
companies_cureyld -->|"includes"| companies_cureyld_2
style companies_cureyld_2 fill:#ffd54f,stroke:#333,color:#000
companies_cureyld_3["Types of Leukodystrophies"]
companies_cureyld -->|"includes"| companies_cureyld_3
style companies_cureyld_3 fill:#ce93d8,stroke:#333,color:#000
companies_cureyld_4["Therapeutic Approaches"]
companies_cureyld -->|"includes"| companies_cureyld_4
style companies_cureyld_4 fill:#4fc3f7,stroke:#333,color:#000
companies_cureyld_5["Gene Therapy"]
companies_cureyld -->|"includes"| companies_cureyld_5
style companies_cureyld_5 fill:#81c784,stroke:#333,color:#000
...Full Name: CureYLD - Curing Youth Leukodystrophies
Headquarters: Boston, Massachusetts, USA
Founded: 2019
Focus: Rare neurological diseases, leukodystrophies, gene therapy
Status: 501(c)(3) nonprofit organization
Website: [cureyld.org](https://www.cureyld.org)
Overview
Mermaid diagram (expand to render)
CureYLD is a nonprofit biotechnology organization dedicated to finding cures for youth leukodystrophies — a devastating group of rare, progressive genetic disorders that affect the white matter of the brain["@cureyld2026"]. Founded in 2019 and headquartered in Boston, Massachusetts, CureYLD bridges the gap between academic research and clinical application, accelerating the development of novel therapies for these devastating neurological conditions.
Leukodystrophies are a class of genetic disorders characterized by abnormal development or destruction of the brain's white matter, which contains the nerve fibers that enable communication between different brain regions. These conditions typically affect children, causing progressive neurological decline including motor impairment, cognitive deterioration, and premature death. With limited treatment options available, CureYLD's mission represents a critical lifeline for affected families.
Mission and Vision
CureYLD's mission is to accelerate the development of curative therapies for leukodystrophies through:
- Funding innovative research in gene therapy, enzyme replacement, and small molecule approaches
- Supporting clinical trials by providing infrastructure and patient recruitment support
- Advocacy and awareness to ensure these rare diseases receive appropriate attention and resources
- Patient and family support programs that provide guidance throughout the diagnostic and treatment journey
The organization collaborates closely with academic medical centers, pharmaceutical partners, and patient advocacy groups to create a comprehensive ecosystem for leukodystrophy research and treatment development.
Science of Leukodystrophies
Disease Mechanism
Leukodystrophies result from genetic mutations that affect the development, maintenance, or function of myelin — the fatty substance that insulates nerve fibers in the central nervous system. When myelin is damaged or fails to develop properly, nerve signal transmission is disrupted, leading to the progressive neurological symptoms characteristic of these disorders[@leukodystrophies2026].
Types of Leukodystrophies
Metachromatic Leukodystrophy (MLD):
- Caused by mutations in the ARSA gene encoding arylsulfatase A
- Leads to accumulation of sulfatides, a type of lipid, in the brain
- Symptoms include motor regression, cognitive decline, and peripheral neuropathy
- Late-infantile form typically presents between 1-2 years of age
Krabbe Disease (Globoid Cell Leukodystrophy):
- Caused by mutations in the GALC gene encoding galactosylceramidase
- Results in accumulation of psychosine, a toxic metabolite
- Characterized by severe neurodegeneration and developmental regression
- Most severe infantile form presents within the first 6 months of life
Adrenoleukodystrophy (ALD):
- Caused by mutations in the ABCD1 gene affecting peroxisomal transport
- Leads to accumulation of very-long-chain fatty acids (VLCFAs)
- Childhood cerebral ALD is the most severe form, causing rapid neurological decline
- Adrenal insufficiency often accompanies neurological symptoms
Canavan Disease:
- Caused by mutations in the ASPA gene encoding aspartoacylase
- Results in accumulation of N-acetylaspartate (NAA) in the brain
- Characterized by macrocephaly, developmental regression, and hypotonia
- Progressive disease with most patients surviving to adolescence
Therapeutic Approaches
Gene Therapy
Gene therapy represents the most promising approach for many leukodystrophies. CureYLD supports programs that deliver functional copies of the defective gene using viral vectors, particularly adeno-associated viruses (AAVs) that can target the central nervous system[@gene2026].
The organization's gene therapy programs include:
- AAV-mediated gene delivery to restore enzyme expression
- Novel vector engineering for improved brain penetration
- Strategies to address immune responses to viral vectors
Enzyme Replacement Therapy
For diseases where the defective enzyme can be provided exogenously, enzyme replacement therapy (ERT) offers a direct approach to restoring metabolic function. CureYLD supports development of recombinant enzyme products that can cross the [blood-brain barrier](/entities/blood-brain-barrier) or be delivered directly to the central nervous system.
Small Molecule Therapies
Small molecule approaches include:
- Substrate reduction therapy: Reducing the accumulation of toxic metabolites
- Chaperone therapy: Helping misfolded proteins achieve proper conformation
- Anti-inflammatory agents: Addressing neuroinflammation that contributes to disease progression
Research Pipeline
Current Programs
| Program | Approach | Disease | Development Stage | Status |
|---------|----------|---------|------------------|--------|
| CY-001 | Gene therapy (AAV) | Metachromatic Leukodystrophy | Preclinical | IND-enabling studies |
| CY-002 | Enzyme replacement | Krabbe Disease | Discovery | Lead optimization |
| CY-003 | Small molecule | Adrenoleukodystrophy | Discovery | Hit-to-lead |
| CY-004 | Gene therapy | Canavan Disease | Research | Proof of concept |
| CY-005 | Gene therapy | Alexander Disease | Research | Target validation |
Upcoming Milestones
- CY-001: Pre-IND meeting with FDA expected in 2026
- CY-002: Candidate selection expected in 2026
- CY-003: Lead candidate nomination expected in 2027
Clinical Programs
Active Clinical Studies
MLD Natural History Study:
- Understanding disease progression in metachromatic leukodystrophy
- Identifying biomarkers for patient stratification
- ClinicalTrials.gov identifier: (TBD)
ALD Natural History Study:
- Characterizing disease progression in adrenoleukodystrophy
- Evaluating endpoints for clinical trials
- Supporting regulatory discussions
Canavan Disease Registry:
- Natural history data collection
- Patient outcomes tracking
- Clinical trial readiness
Collaboration with Clinical Centers
CureYLD partners with leading academic medical centers including:
- Boston Children's Hospital
- University of Minnesota Leukodystrophy Center
- Children's Hospital of Philadelphia (CHOP)
- University of California, San Francisco
Organization Structure
Leadership and Governance
CureYLD is led by a dedicated team with expertise in rare disease research, drug development, and patient advocacy:
- Scientific Advisory Board: Composed of leading researchers in leukodystrophy biology and gene therapy
- Clinical Advisory Board: Includes neurologists and pediatric specialists with extensive experience in leukodystrophy care
- Patient Advocacy Council: Ensures patient perspectives inform all organizational decisions
Funding Sources
As a nonprofit organization, CureYLD relies on diverse funding sources:
- Private foundations and charitable donations
- Individual supporters and family foundations
- [Pharmaceutical](/companies) partnership agreements
- Government research grants
Financial Transparency
Annual reports and financial statements are publicly available, ensuring donors and stakeholders can track the organization's impact and resource allocation.
Impact and Achievements
CureYLD serves as a vital resource for the leukodystrophy community:
- Patient navigation services: Helping families understand diagnosis, treatment options, and clinical trial opportunities
- Educational resources: Providing up-to-date information on disease mechanisms and therapeutic approaches
- Family support programs: Connecting affected families with resources and each other
- Advocacy efforts: Working with policymakers to increase awareness and funding for leukodystrophy research
Research Contributions
Since its founding in 2019, CureYLD has:
- Funded over $15 million in leukodystrophy research
- Supported 12 active research programs
- Helped advance 3 programs toward clinical development
- Established partnerships with 8 academic institutions
- Built a patient registry with over 500 enrolled families
Key Achievements
- 2020: Launched first research grant program
- 2021: Established clinical advisory board
- 2022: Initiated first IND-enabling studies for CY-001
- 2023: Entered first pharmaceutical partnership
- 2024: Expanded pipeline to 5 active programs
Partnerships and Collaborations
Academic Partnerships
CureYLD collaborates with leading research institutions:
- Harvard Medical School: Gene therapy vector development
- University of Pennsylvania: Canavan disease research
- University of Michigan: Biomarker discovery
- Stanford University: Small molecule screening
Pharmaceutical Partnerships
Strategic alliances with pharmaceutical companies support clinical development:
- Manufacturing partnerships for clinical supply
- Regulatory expertise for IND submissions
- Commercial development planning
Patient Advocacy Organizations
CureYLD works closely with patient advocacy groups:
- United Leukodystrophy Foundation (ULF)
- MLD Foundation
-ALD Connect
- Canavan Disease Foundation
Future Directions
Looking ahead, CureYLD is focused on:
Advancing the clinical pipeline: Moving CY-001 and subsequent programs into clinical trials
Expanding research portfolio: Identifying and funding new therapeutic approaches
Building clinical infrastructure: Establishing sites capable of conducting leukodystrophy clinical trials
International expansion: Extending reach to serve patients globally
Platform development: Creating tools and resources to accelerate all leukodystrophy programsSee Also
- [Leukodystrophies](/diseases/leukodystrophies)
- [Metachromatic Leukodystrophy](/diseases/metachromatic-leukodystrophy)
- [Krabbe Disease](/diseases/krabbe-disease)](/diseases/krabbe-disease)
- [Adrenoleukodystrophy](/diseases/adrenoleukodystrophy)
- [Canavan Disease](/diseases/canavan-disease)](/diseases/canavan-disease)
- [Gene Therapy](/technologies/gene-therapy)](/technologies)
- [AAV Vectors](/technologies/aav-vectors)](/technologies)
- [Enzyme Replacement Therapy](/technologies/enzyme-replacement-therapy)](/technologies)
- [Rare Disease Research](/topics/rare-disease-research)
External Links
- [CureYLD Official Website](https://www.cureyld.org)](/companies/cureyld)
- [Clinical Trials](https://clinicaltrials.gov)](/clinical-trials)
- [United Leukodystrophy Foundation](https://ulf.org)
- [MLD Foundation](https://mldfoundation.org)
References
CureYLD, Our Mission (2026)
Leukodystrophies, National Institute of Neurological Disorders and Stroke (2026)
Gene Therapy, FDA Cellular & Gene Therapy Products (2026)